Researcher
Elisa Ardizzoni
Affiliations
- Mycobacteriology (Research unit)
Member
From1 Mar 2009 → Today - Mycobacteriology (Research unit)
Member
From28 Feb 2009 → 16 Apr 2015
Projects
1 - 7 of 7
- TB/NTM Research ClusterFrom1 Jan 2022 → Today
- EndTB-Q Output 5 testing new regimens to treat MDR-TB resistant to fluoroquinilonesFrom1 Jul 2020 → Today
- MSF Routine ServicesFrom1 Mar 2020 → 28 Feb 2024
- Effectiveness and tolerability of a short regimen for drug resistant tuberculosis treatment in Kandahar Province, Afghanistan, Uncontrolled Clinical StudyFrom1 Sep 2019 → 30 Apr 2022
- Treatment of Rifampin-resistsant Tuberculosis with an All-Oral Regimen containing new drugs in Zhytomyr UkraineFrom1 Mar 2019 → 31 Jul 2021
- End TB Clin.Trial Output 2From1 Jun 2016 → 31 Aug 2023
- Improving detection of drug-resistant tuberculosis (TB by use of novel phenotypic and genotypic testsFrom1 Jan 2013 → Today
Publications
1 - 10 of 15
- Middlebrook 7h11 reduces invalid results and turnaround time of phenotypic drug‑susceptibility testing of M. tuberculosis(2022)
Authors: Rupasinghe Arachchige Praharshinie Rupasinghe, Jens Vereecken, Pieter Graulus, Tom Decroo, Elisa Ardizzoni, Cathy Hewison, Dimitri Donchuk, Helena Huerga, Anita Mesic, Leen Rigouts, et al.
Pages: 407-411 - Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment(2022)
Authors: Sophia B. Georghiou, Timothy C. Rodwell, Alexei Korobitsyn, Said H. Abbadi, Kanchan Ajbani, Jan-Willem Alffenaar, David Alland, Nataly Alvarez, Sonke Andres, Elisa Ardizzoni, et al.
- Thin-layer-agar-based direct phenotypic drug susceptibility testing on sputum in Eswatini rapidly detects Mycobacterium tuberculosis growth and rifampicin resistance otherwise missed by WHO-endorsed diagnostic tests(2021)
Authors: Elisa Ardizzoni, E. Ariza, D. Mulengwa, Q. Mpala, R de la Tour, Gugu Maphalala, F. Varaine, Bernhard Kerschberger, Pieter Graulus, A-L Page, et al.
- Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial(2021)
Authors: L. Guglielmetti, Elisa Ardizzoni, M. Atger, E. Baudin, E. Berikova, M. Bonnet, E. Chang, Sandrine Cloez, J. M. Coit, J Cox, et al.
- Evaluation of OMNIgene Sputum and ethanol reagent for preservation of sputum prior to Xpert and culture testing in Uganda(2020)
Authors: Elisa Ardizzoni, Patrick Orikiriza, Charles Ssuuna, Dan Nyehangane, Mourad Gumsboga, Ivan Mugisha Taremwa, Esther Turyashemererwa, Juliet Mwanga-Amumpaire, Celine Langendorf, Maryline Bonnet
- MDR M. tuberculosis outbreak clone in Eswatini missed by Xpert has elevated bedaquiline resistance dated to the pre-treatment era(2020)
Authors: Patrick Beckert, Elisabeth Sanchez-Padilla, Matthias Merker, Viola Dreyer, Thomas Andreas Kohl, Christian Utpatel, Claudio U. Koeser, Ivan Barilar, Nazir Ismail, Shaheed Vally Omar, et al.
- Incremental yield of including Determine-TB LAM assay in diagnostic algorithms for hospitalized and ambulatory HIV-positive patients in Kenya(2017)
Authors: Helena Huerga, Gabriella Ferlazzo, Paolo Bevilacqua, B Kirubi, Elisa Ardizzoni, Stephen Wanjala, Joseph Sitienei, Maryline Bonnet
- Nontuberculous Mycobacteria infections at a provincial reference hospital, Cambodia(2017)
Authors: Maryline Bonnet, Kim Chamroeun San, Yati Pho, Chandara Sok, Jean-Philippe Dousset, William Brant, Northan Hurtado, Khun Kim Eam, Elisa Ardizzoni, Seiha Heng, et al.
Pages: 1139-1147 - Correlation of different phenotypic drug susceptibility testing methods for four fluoroquinolones in Mycobacterium tuberculosis(2016)
Authors: Nele Coeck, Bouke de Jong, Maren Diels, Pim De Rijk, Elisa Ardizzoni, Armand Van Deun, Leen Rigouts
Pages: 1233-1240 - Routine use of Xpert® MTB/RIF in areas with different prevalences of HIV and drug-resistant tuberculosis(2015)
Authors: A-L Page, Elisa Ardizzoni, M Lassovsky, B Kirubi, D Bichkova, A Pedrotta, C Lastrucci, R de la Tour, M. Bonnet, F. Varaine
Pages: 1078-1083, i-iii